ScreenerHero

ESLA Estrella Immunopharma, Inc.

NAS · US · Healthcare · Biotechnology · estrellabio.com
0.4193USD-2.26%Mkt Cap: 18.24M $P/E: —

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap18.24M USD
Enterprise Value18.51M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-13.06M USD
Revenue/Share—
Last Price0.4193 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.34
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-2.48
EPS (TTM)-0.24
EPS (Forward)-0.32
52W Range
0.41120% of range3.150
52W High3.150 USD
52W Low0.4112 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE126.02%
ROA-411.19%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.79M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-37.22%
Net Debt-146.67K USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio0.20
Quick Ratio0.02
Book Value/Sh-0.17 USD
Cash/Share0.0030 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)12.00 USD
Upside (mean)+2761.9%
Target Range12.00 USD – 12.00 USD
# Analysts1
Ownership
Shares Out.43.50M
Float38.21M
Insiders60.42%
Institutions11.14%
Short Interest
Short Ratio4.2d
Short % Float0.88%
Short % Out.0.35%
Shares Short153.78K
Short (prev mo.)61.41K
Technical
SMA 500.6481 (-35.3%)
SMA 2001.069 (-60.8%)
Beta0.93
S&P 52W Chg16.45%
Avg Vol (30d)36.52K
Avg Vol (10d)27.24K
Technical Indicators
RSI (14)24.2
MACD-0.0699
MACD Signal-0.0696
MACD Hist.-0.0003
BB Upper0.6938 USD
BB Middle0.5194 USD
BB Lower0.3449 USD
BB Width67.19%
ATR (14)0.0554 USD
Vol Ratio (20d)1.26x